Stay Awesome
Updates & News
You didn’t come this far to stop learning
CLICK ON A VACCINE FOR A DEEPER DIVE
Anthrax - Chikungunya - Cholera - COVID-19 - Diphtheria - Dengue - Gonorrhoea - Hepatitis A - Hib - Hepatitis B - Hepatitis A - HPV - Influenza - Japanese Encephalitis - Measles - Meningococcal - Mpox - Mumps - Pertussis - Pneumococcal - Poliomyelitis - Rabies - Rotavirus - RSV - Rubella - Shingles - Tetanus - Tick Borne Encephalitis - Tuberculosis - Typhoid - Varicella - Yellow Fever
(all the vaccine-related news items below also go into the individual portals if you want to concentrate on updates for a specific disease)
November 2026
UPDATES FOR ALL
Mini flu bulletin here in the latest Vaccine Update newsletter with some more resources to explore. See the bigger issue here which has tonnes of useful links and resources in.
Government accepts advice on spring 2027 COVID-19 vaccinations - nothing new for Spring eligibility ... The programme will run for 11 weeks, from 5 May to 21 July 2027.
3rd Nov 2026: Pneumococcal green book chapter revised to to update the history and epidemiology of disease section, the dosage and schedule section, include Down syndrome as a specific clinical risk group, and update tables 3a and 3b for clarity, including vaccines for use.
6th Nov 2026: COVID-19 vaccination: information for healthcare practitioners updated. This is a very useful document if you haven't seen it before. It includes detailed information on the background of the programme, the vaccines (as they become available- it gets updated a lot), vaccine recommendations and eligibility, contraindications and precautions and vaccine administration issues. well worth a gander.
CHILDHOOD/ADOLESCENT/YOUNG ADULT IMMUNISATION NEWS
Td/IPV (3-in-one) teenage vaccine: VGD template has landed!!! Also the PGD has been updated too.
It's chickenpox vaccine catch up time now for those age 4-6 who missed out when this vaccine was introduced in Jan 2026. Best of luck with it. This article came out just in time: New report shows toll of Chickenpox with over 3,000 infants hospitalised last year. An MMRV training slideset for is available to download if you are a bit confused by it all... (I'm sure you won't be alone there). There are also posters and leaflets available to assist. And here is the new epidemiological reports section on varicella.
6th Nov: UKHSA MenB PGD template amended to add the use of Trumenba (frLP2086) for the prevention of secondary cases of meningococcal group B disease as per Guidance for public health management of meningococcal disease in the UK and subsequent changes to lots of other sections because of it. Other changes are updated cautions and patient advice to include advice for driving and using machines, removal of subcutaneous use for bleeding disorders from off-label and route and administration sections as per updated Green Book Meningococcal Chapter, Green Book, updated references, and some minor rewording, layout and formatting changes for clarity and consistency with other UKHSA PGDs.
New York child dies from measles in state’s first fatal case in 30 years
TRAVEL HEALTH NEWS
I'm looking forward to another fabulous BGTHA conference this month. Register here if not already :-)
There is another educational even hosted by Valneva on 19th Nov at 4pm all about Japanese Encephalitis, delivered by one of my favourite pharmacisists, Derek Evans. Always a great speaker. Register here.
Uganda imposes 21-day quarantine on citizens returning from Congo
This was a good find! Beware ‘sun, sea and surgery’ cosmetic tourism packages, experts advise - this article mentions a checklist for those getting cosmetic surgery abroad and you can see it here: “Vet It Before You Get It”: Empowering the Public to Choose Safely
A healthcare worker from the UK has been evacuated from DRC back to the UK to receive treatment after testing positive with Ebola. Deaths from Bundibugyo Ebola in DRC have sadly reached almost 5,000 and the number of cases is now above 10,000.
6th Nov: Some tweaks made to the JCVI advice on the use of Chikungunya vaccines for UK travellers now IXCHIQ has lost its licence. Given the safety signal of concern has only been associated with IXCHIQ, JCVI does not consider it necessary to advise additional restrictions on the use of Vimkunya. Green Book chapter, where are youuuuu?
ADULT IMMUNISATION NEWS
Schedule in some time to have a look at the new toolkit to support vaccination among people experiencing homelessness and all the useful resources that go with it.
5th Nov: RSV vaccination coverage in England for the maternal and older adult programmes are in for the month of June. These figures show that RSV vaccination uptake in England has largely stabilised, with maternal coverage at 62.0% and older-adult coverage at 63.5%. Uptake continues to improve slowly in the older-adult catch-up cohort (69.2%), but substantial inequalities in vaccine coverage persist across regions and population groups.
My reading list this month
Antarctica: Avian cholera identified as primary driver of mass Adélie penguin deaths, not H5N1
Developing and benchmarking one health genomic surveillance tools for influenza A virus in wastewater - Nature Communications
Claude helped plan risky bird flu research. What did the AI add?
First participant vaccinated in pivotal Phase 2/3 Bundibugyo vaccine trial in DRC
Needle-free mRNA vaccines protect mice against COVID-19 and flu
This is an age of anti-vaccine unreason – and even NHS staff are not immune
I wrote three new blogs last month (got a bit obsessed with Polio. It's my polio hat trick!)
October 2026
UPDATES FOR ALL
Well flu and Covid vaccine clinics will be getting in full swing now. Hope it's going well!
Very pleased to see resources arriving in preparation for the new flu/pneumococcal eligible groups: Vaccination resources for people experiencing homelessness (PEH). These resources are to promote the availability of the flu and pneumococcal vaccines for those experiencing homelessness. And here is some useful guidance (and examples of good practice) Supporting vaccination of people experiencing homelessness: A multi-agency toolkit for planning and delivery of vaccinations to people experiencing homelessness. This was published in June 2026 and is also worth checking out: Understanding and addressing immunisation inequities toolkit
Important point: GP practices delivering the seasonal flu enhanced service can vaccinate eligible PEH even if they are not registered with the practice. For pneumococcal vaccination, however, GP practices can only vaccinate eligible PEH who are registered patients; unregistered patients should be offered registration or signposted to locally commissioned services. This does feel a bit incongruous because the rationale behind adding PEH to these programmes explicitly recognises that this population has poor access to routine healthcare, low vaccine uptake and benefits from outreach/opportunistic delivery. Could more opportunities be missed here?
Housebound flu and COVID vaccination: GP practices participating in the seasonal COVID-19 and/or flu vaccination services must ensure that all eligible housebound patients are offered vaccination. Practices not participating should signpost patients to the appropriate local housebound or specialist vaccination service. NHS 119 cannot book housebound vaccination appointments and will direct patients back to their GP practice.
Another important update: Fluenz; be aware of increased risk of fainting following administration. The product information for Fluenz has been updated to reflect that there is an increased risk of syncope (fainting) immediately following administration of the nasal spray, particularly if the individual has previously fainted following vaccination. Procedures should be put in place to prevent injury from fainting and manage syncopal reactions. Due to timing constraints, this information is not included in the patient information leaflet for this season’s campaign. Therefore, please ensure that parents and patients are informed of this potential risk before administration.
Vaccination of people with uncertain or incomplete immunisation: Updated to include those eligible for the RSV vaccine who are aged 65 to 74 in some clinical risk groups.
7th Oct: Nurse struck off after flu vaccination medication error: headlines reported that a nurse was struck off after accidentally administering adrenaline instead of flu vaccine during a home visit. The full NMC decision shows a much broader picture, involving subsequent medication errors and later failure to demonstrate remediation. A useful reminder to look beyond the headline and some useful practice learning points too regarding off site visits- read the news article alongside the tribunal decision.
12th October: New materials for promoting flu vaccines in the extra 'vaccine update' bulletin. Cases of flu in September were higher than usual in England. Eligible people are being urged to get their flu vaccinations as soon as possible. Have you had yours yet?
19th Oct: New equity slide set!!
19th Oct: New translations added to the COVID-19 vaccination: autumn programme resources and also to the RSV programme respources.
22nd Oct: Press release- Social media campaign urges Brits to get vaccinated for winter: Government launches a social media campaign to promote a new NHS App feature which helps people check their eligibility and book their flu vaccination
CHILDHOOD/ADOLESCENT/YOUNG ADULT IMMUNISATION NEWS
1st Oct: Over 212,000 get the first MenB dose but almost 75% missing out. UKHSA is urging young people to get vaccinated with 2 doses for protection.
Useful materials for the November catch ups: MMRV single dose selective catch up resources: These resources are to promote the offer to parents of children eligible for a catch up single dose of MMRV vaccine. The selective MMRV catch-up programme will run from 1 November 2026 to 31 March 2028, offering MMRV to eligible children born between 1 January 2020 and 31 August 2022 who have no history of chickenpox and have not received two doses of a varicella-containing vaccine. Worth noting: During November and December 2026, automated CQRS payments will only cover children aged 5 years and under at vaccination; practices vaccinating eligible 6-year-olds will need to make a manual CQRS adjustment.
9th Oct: MenB: protecting your baby against meningitis and septicaemia: Updated 3-minute guide for parents explaining the MenB vaccine and meningococcal disease.
15th Oct: AI could help predict which HPV infections progress to cancer
28th Oct: Meningococcal Green Book chapter updated to include additional information in the administration section for those on anticoagulation therapy or those with bleeding disorders.
TRAVEL HEALTH NEWS
Ixiaro = NOW BACK IN STOCK yay!
7th Oct: BUT ALSO BIG NEWS FOR VALNEVA: IXCHIQ chikungunya vaccine withdrawn from the UK! The MHRA has revoked the UK marketing authorisation for IXCHIQ, Valneva’s live attenuated chikungunya vaccine, following a further benefit–risk assessment by the Commission on Human Medicines. The decision is based on previously known safety data and is not associated with any newly identified safety signal. Valneva had already stopped actively distributing IXCHIQ in the UK and reports that no stock remains on the UK market. The decision does not affect IXCHIQ licences in the EU or other countries.
8th Oct: Kenya has confirmed its first case of Bundibugyo Ebola virus...and a second case on 14th Oct - a 39-year-old man who is a close relative of the first case and was already in quarantine when he fell ill :-(
WHO has published its latest global update on cholera, meningitis and plague. In 2025, 47 countries reported 451,499 cholera cases and 7,870 deaths, with deaths rising by 30% despite fewer reported cases overall. Seven countries accounted for around 90% of reported cholera cases and deaths, while Africa saw the greatest burden. Oral cholera vaccine production has more than doubled since 2022, reaching around 80 million doses annually. In the African meningitis belt, 21,526 suspected meningitis cases and 971 deaths were reported in 2025, while rollout of the broader Men5CV vaccine continues. WHO also reported 3,847 suspected human plague cases and 423 deaths globally between 2019 and 2025, mainly in the DRC and Madagascar.
Meanwhile, not too far from home!! Concerns as children seriously ill after beach trips: A three-year-old child was admitted to hospital and subsequently confirmed by blood testing to have hepatitis A after visiting Avon Beach in Dorset during the summer. Her family believes the infection may have been acquired during the visit, although the source has not been confirmed. The Environment Agency is carrying out additional inspections and water sampling around Christchurch Harbour following reports of illness in several children who had spent time in the area.
If you missed the Valneva cholera webinar this month don't panic! It's here: Webinar: Cholera Risk in Today’s Traveller
Recent reports are a useful reminder of the varied ways travellers may encounter rabies. Rabies alerts have been issued in several US states following infections in animals including bats, raccoons and foxes; in Bali, a four-month-old pet puppy that bit three members of one family was confirmed rabies-positive; and in South Africa, rabies continues to circulate amongst Cape fur seals, with beachgoers warned to keep their distance. These cases reinforce that rabies risk is not limited to stray dogs.
Oct 14th: Mosquito saliva study opens new doors for blocking Zika, Dengue, and West Nile infections
Oct 15th: ‘I ached so much’: Man describes bout with dengue fever contracted during Florida’s outbreak.
Getting to grips with Zika virus: A recording of the latest NaTHNaC session on 15th October is now available
ADULT IMMUNISATION NEWS
1st October: Hepatitis A/B vaccine: patient group direction template updated - removal of chronic hepatitis B from the inclusion criteria because giving hepatitis B in such circumstances is futile and monovalent hepatitis A vaccine would be more appropriate. The hepatitis A PGD template has also been updated just with some minor rewording, layout and formatting changes for clarity and consistency with other UKHSA PGD templates
1st October: RSV vaccine uptake data published: marked inequalities remain. Latest UKHSA data continue to show substantial inequalities in RSV vaccine uptake across both the maternal and older-adult programmes.
Among women giving birth in May 2026, maternal RSV vaccine uptake was 62.2% overall. However, uptake varied considerably by ethnicity, ranging from 78.5% among Chinese women to 39.2% among Black Caribbean women. Uptake was also lower among Pakistani women (46.6%) and women from other Black backgrounds (44.7%). Large geographical variation was seen, from 82.3% in the highest-uptake local authority to 35.9% in the lowest.
For older adults, overall uptake by the end of August 2026 was 62.9%, but clear socioeconomic and ethnic inequalities remain. Uptake increased steadily with decreasing deprivation, from 50.0% in the most deprived decile to 71.0% in the least deprived. By ethnicity, uptake ranged from 66.5% among White British adults to just 25.3% among Pakistani adults, with similarly low uptake among Bangladeshi (27.5%), Black Caribbean (28.0%) and Black African (29.7%) groups. Age/cohort differences are also evident: uptake in the original 75–79-year catch-up cohort was 69.6%, compared with only 46.9% in the routine cohort of people turning 75 since the programme began, suggesting continued challenges in reaching newly eligible adults.
These figures highlight that improving overall RSV coverage alone is not enough; targeted approaches are needed to address persistent inequalities by deprivation, ethnicity and age/cohort.
8th Oct: Vaccines in pregnancy: advice for pregnant women inadvertently immunised with MMR, chickenpox or shingles vaccines updated to include MMRV.
My reading list this month
Adjuvanted and high-dose flu vaccines show similar effectiveness in older adults: A US study of more than 37,000 adults aged 65 and over found no significant difference in effectiveness between adjuvanted and high-dose influenza vaccines in preventing laboratory-confirmed flu or hospitalisation. Both vaccines are designed to improve protection in older adults, whose immune response to vaccination can be reduced with age. The findings add to previous research suggesting that both enhanced vaccine approaches offer broadly comparable protection. The study was funded by CSL Seqirus, manufacturer of the adjuvanted influenza vaccine Fluad.
UK rabies vaccine trial could also unlock protection against Disease X: A first-in-human UK trial has begun testing a new self-amplifying RNA rabies vaccine developed by Imperial College London. Around 48 healthy adults will take part in the study, which will assess safety and immune responses. The technology is designed to use smaller amounts of RNA than conventional mRNA vaccines and could potentially make vaccines easier and cheaper to manufacture. Researchers hope the same platform could eventually be rapidly adapted to produce vaccines against newly emerging infections — including a future unknown “Disease X”.
Assessment of the healthcare burden of dengue disease in England: a retrospective analysis (2010–2023). This retrospective study of NHS data from 2010–2023 has found an increasing burden of imported dengue in England. Among 596 people hospitalised with dengue, admission rates rose over the study period, peaking in 2019 and increasing again from 2022 following the COVID-19 pandemic. Around one-third of hospitalised cases were in adults aged 18–29 years, and around 20% of patients had a subsequent hospital admission. The study also identified 2,286 suspected dengue cases recorded in primary care, of which 1,220 were confirmed. A supplementary analysis showed hospitalised dengue incidence had risen back to around 5 per million person-years by 2024, after dropping sharply during the pandemic. The paper also notes that UK reported dengue cases increased from 631 in 2023 to 904 in 2024, all associated with travel abroad. The authors highlight the need for targeted public health measures for travellers, particularly younger adults, as well as improved recording of suspected dengue, symptoms and travel history in general practice.
Measles death toll exceeds 1100 as Bangladesh struggles with outbreak: Bangladesh is experiencing a major measles outbreak, with more than 200,000 suspected cases reported since March 2026. The BMJ reports that the true death toll could now exceed 1,100, with children accounting for most deaths, although official confirmed figures are lower. Falling routine vaccination coverage and accumulated immunity gaps are thought to have contributed to the outbreak. The government, supported by WHO and partners, has launched emergency vaccination campaigns and an independent review of the national immunisation programme.
31-valent pneumococcal vaccine passes Phase 3 trial: Vaxcyte’s experimental 31-valent pneumococcal conjugate vaccine, VAX-31, has produced encouraging Phase 3 results in adults aged 50 and over. The vaccine met non-inferiority criteria for the 28 serotypes it shares with existing higher-valency pneumococcal vaccines, while also generating strong responses to three additional serotypes unique to VAX-31. If successfully licensed, it could offer broader protection against invasive pneumococcal disease and pneumococcal pneumonia. Further Phase 3 results are expected in 2027, with a US licence application currently planned for 2028.
Dengue outbreak continues in Florida: Florida is experiencing an unusually large outbreak of locally acquired dengue, centred particularly around Tampa and Hillsborough County. More than 250 locally acquired cases had been reported by late September, alongside a dengue-associated death, with transmission continuing into October. It is a useful reminder that dengue risk is not restricted to destinations traditionally thought of as tropical — mosquito bite avoidance remains an important part of travel health advice.
Controversy over proposed hepatitis B vaccine trial in Guinea-Bissau: A proposed CDC-funded study involving 14,000 newborns in Guinea-Bissau has attracted significant ethical criticism. The study would compare hepatitis B vaccination at birth with vaccination at six weeks, which is currently the country's routine schedule. Critics, including WHO, argue that withholding the birth dose for research purposes is difficult to justify when its effectiveness in preventing perinatal transmission is already well established. Although a revised protocol has received approval from a Danish university, national authorisation in Guinea-Bissau has not yet been granted.
HPV vaccination linked with improved pregnancy outcomes: A large Swedish study involving more than 624,000 births has found that women vaccinated against HPV before pregnancy had lower rates of several adverse pregnancy outcomes, including preterm and very preterm birth. The association was particularly noticeable among women vaccinated before the age of 17. As this was an observational study it cannot prove that HPV vaccination itself caused the reduction, but it adds an interesting potential additional benefit to the already well-established cancer prevention offered by HPV vaccination.
Could AI help remove the cold chain from future mRNA vaccines?: Researchers have used an AI-guided approach to develop more heat-stable formulations of the lipid nanoparticles used to deliver mRNA vaccines. Experimental solid formulations retained activity after storage at 37°C for more than two months, and produced immune responses comparable with fresh formulations in animal studies. The technology is still experimental, but could eventually have major implications for vaccine storage, distribution and access, particularly in settings where maintaining a reliable cold chain is difficult.
First personalised cancer vaccine cuts risk of disease returning in major trial. A personalised mRNA cancer vaccine given with immunotherapy cut the risk of melanoma returning or death by 42% in a major Phase III trial involving 1,137 patients. Read the full ESMO report here: ESMO – INTerpath-001 Phase III results
Just a bit of seasonal fun.....
September 2026
UPDATES FOR ALL
There is a webinar this month on the 23rd September 1-4pm by the RCN called Vaccination: Nursing staff roles and responsibilities. Could be a good'n! I'm also looking forward to attending the PCN Roadshow later this month in London. Hope to see you there :-) And more CPD: early bird registration is now open for the Global TB Summit 2026 in October.
And another free webinar is coming up this month (30th Sept, 10-4) for RCN members which is worth considering, especially given the big focus on health inequalities at the moment: Supporting people with learning disabilities across the lifespan. NHSE has published new guidance to improve the identification of people with a learning disability and strengthen the delivery of annual health checks and health action plans.
3rd Sept: The FLU POSTER is here! I don't know about you but I always finally feel like it all makes more sense when this arrives...
3rd Sept: More posters (and magnet) updates - the 'keep your vaccines healthy' poster and magnet have been updated with a new design (nice polar bear this time) and product code, with no change to the content itself.
9th Sept: Vaccine update has landed! It's a flu bonanza!!! This was highlighted and I found it very interesting: webinar recording: Seasonal flu vaccine 2026/27 – preparing your school for the autumn programme. This was also released from UKHSA today: Who’s eligible for the 2026 COVID-19 vaccine, or ‘Autumn Booster’?
15th Sept: Vaccination of people with uncertain or incomplete immunisation: New supporting guidance document for healthcare professionals
16th Sept: COVID updates galore!!! Updates have been published today in the Green Book and info for healthcare professionals doc - plus we have a PGD and a VGD!! Keep an eye out for ELfHC updates. Find updated leaflets and stickers here!! And the poster is here!
23rd Sept: ELfHC COVID-19 module has landed!!! So has the latest vaccine update newsletter from UKHSA, which is very useful and includes one of my favourite subjects: RABIES!!
24th Sept: Updated Complete routine immunisation schedule AND the visual guide to vaccines poster: time to get the laminator out again! Versions for use from September 2026 now include the expanded RSV eligibility.
24th Sept: Pertussis: laboratory confirmed cases reported in England 2026 PUBLISHED! And PROMISING!! The summary is: Cases have fallen markedly: 71 laboratory-confirmed pertussis cases in England in Jan–Mar 2026, compared with 328 in Jan–Mar 2025 (around a 78% reduction!). Infant cases remain very low: only 3 cases in infants under 1 year, including 1 under 3 months. No infant deaths from confirmed pertussis were reported in Jan–Mar 2026. Maternal vaccine uptake has improved: 74% in Q1 2026, 2.7 percentage points higher than Q1 2025, although still below the historic peak. Childhood uptake: 3-dose coverage at 12 months was 90.5%, down 0.8 percentage points; preschool booster coverage was 81.9%, up 0.6 percentage points.
CHILDHOOD/ADOLESCENT/YOUNG ADULT IMMUNISATION NEWS
There have now been 250,000 MenB vaccines given to young people in England between 20 July and 31 August. Well done all!!!
10th Sept 2026: Invasive meningococcal disease in England: annual laboratory-confirmed reports for epidemiological year 2025 to 2026: 348 cases of IMD were confirmed from July 25 to June 26. MenB accounted for 88.8% (309 of 348) of all cases, followed by MenW (19, 5.5%), MenY (5, 1.4%), and MenC (2, 0.6%). 11 ungroupable cases were also reported. MenB was responsible for the majority of IMD cases in individuals under 25 years of age. The provisional IMD case fatality ratio (CFR) in England was 7.5% (26 of 348).
18th Sept: Hexavalent combination vaccine: update to the programme guidance: the number of hepatitis-B containing vaccine doses for children flowchart amended for clarity.
22nd Sept: TB, BCG and your baby poster containing QR codes for translations of the leaflet has been added
25th Sept: Pneumococcal vaccination programmes for infants, adults and individuals at increased clinical risk: Added easy read guide to the pneumococcal vaccine leaflet.
Having learned lots of lovely new information at yesterday's PCN conference I've come across this fantastic resource for handling conversations around school-aged vaccines which I've added to the hesitancy and uptake section of the site. Check it out!!
TRAVEL HEALTH NEWS
There is a webinar this month hosted by Valneva called Beyond the Outbreak: Rethinking Cholera Risk in Today’s Traveller (HCPs only). It's on the 17th Sept at 4pm with the lovely Simon Carvell. If you can't make it sign up anyway for the recording! Also on that day is a (free) RCPSG webinar 1230-1300 which explores the topic of travel information for people with cancer. Book that here.
Don't forget, there's also the fabulous RCN/NaTHNaC joint conference on 26th September too!
1st Sept: BMJ news: West Nile virus death is confirmed in Netherlands. and West Nile virus: spread rises again in Greece as authorities stay on alert.
9th Sept: Ixiaro should be back in stock again soon! Yay! Valneva anticipate having good supply of Ixiaro again for the rest of this year.
14th Sept: The Rabies risk assessment form has been removed now but is still being used by the clinicians at UKHSA. Worth following this advice in the event of a post eposure client and getting as much info as you can relating to the bullet points if you need to call about them.
15th Sept: WHO Guidelines for malaria now include Coartem® Baby for newborns and young infants
21st Sept 2026: Dengue Green Book Chapter updated: see the portal for more info.
ADULT IMMUNISATION NEWS
3rd Sept 2026: The annual overview of respiratory syncytial virus (RSV) surveillance results from the winter period is available for perusal....Also, uptake data has landed for both the maternal and older adult RSV programmes.
8th Sept: The Pneumococcal Info for HCPs guidance has now been updated to include people who experience homelessness (PEH) as a new risk group from 1st October 2026. They have also added further clarification of risk group information, and revised the text about use of PPV23 and PCV20 now that the latter is available to order. They also added a health equity statement.
9th Sept: WHO prequalifies multi-dose RSV vaccine vial, paving the way to protecting more infants globally
My reading list this month
Rabid Beaver Alert!!! Beaver at Maryland state park tests positive for rabies following latest attack
and... thanks for this one Fray....Rabid seals bite at least 176 people as fatal disease spreads, threatening other species
Nigeria’s Lassa fever death count surpasses 2025 as outbreak worsens
Governors commit to accelerating leprosy elimination across Indonesia. Indonesia remains among the countries with the highest leprosy burden globally, with more than 16 000 new cases reported in 2025. Children accounted for 9.1% of new cases, showing that transmission is still occurring in households and communities.
22nd Sept: Oh Trump :-( Trump: “Split vaccines into five doses to reduce autism”—the US president’s latest unevidenced claim (BMJ peice)
Rotavirus vaccine shows strong global results in preschoolers
RSV vaccine effective against hospitalization, death in nursing home residents
Scientists in China discover new tick-borne virus that causes flu-like illness
New typhoid conjugate vaccine from EuBiologics receives WHO prequalification
New “blockbuster” tuberculosis vaccines could save seven million lives by 2050
